Genoscience Pharma announces launch of phase 2b clinical trial of ezurpimtrostat (GNS561) to treat hepatocarcinoma in combination with an immune checkpoint inhibitor and an antiangiogenic agent
Read the press release: https://www.genosciencepharma.com/2023/01/06/genoscience-pharma-starts-its-phase-2b-clinical-trial-of-gns561/
